Awareness of oncology residents and clinical oncologists regarding the application of the Go Wish Cards Game for cancer patients: a multicenter pre and post-intervention study

Start Date07 Apr 2025

Sponsor / Collaborator

Barretos Cancer Hospital

[+1]

NCT06881940

/ Not yet recruitingNot ApplicableIIT

Rationale and Design of a Cardiac Rehabilitation Program on the Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Treatment with Anthracyclines And/or Trastuzumab: a Randomized, Active Control Group, Open-Label Trial

This study aims to evaluate the effectiveness of a cardiac rehabilitation protocol, incorporating aerobic and resistance exercise, in reducing the incidence of cardiotoxicity in breast cancer patients receiving treatment with anthracyclines and/or trastuzumab through a randomized, active control group, open-label clinical trial.

Start Date01 Apr 2025

Sponsor / Collaborator

Instituto Nacional de Cardiología Ignacio Chávez

[+1]

RBR-8h6tk9z

/ Not yet recruitingNot ApplicableIIT

Evaluation of the effects of Auriculotherapy to control pain in lesions or tumor wounds in patients with advanced cancer undergoing palliative care

Start Date03 Oct 2024

Sponsor / Collaborator

Instituto Nacional de Cancerología

[+1]

100 Clinical Results associated with Instituto Nacional de Cancerología

0 Patents (Medical) associated with Instituto Nacional de Cancerología

3,707

Literatures (Medical) associated with Instituto Nacional de Cancerología

01 Jul 2025·Archives of Medical Research

Narrowing the Gap: Understanding Lung Cancer Care Intervals and Their Barriers in Latin American Low and Middle-Income Countries

Article

Author: Williams, Haydee ; Muñoz-Montaño, Wendy R ; Reynoso-Noverón, Nancy ; Arrieta, Oscar ; Rios-Garcia, Eduardo ; Corona-Cruz, Jose ; Cores, Vanessa ; Flores-Estrada, Diana ; Gómez-García, Ana Pamela ; Palomares-Palomares, Cittim B ; Cardona, Andrés F ; Turcott, Jenny G ; Hernandez-Martinez, Juan-Manuel

BACKGROUND AND AIMSBarriers in lung cancer (LC) management impact patient care and their outcomes, yet studies from high-income countries may not be fully applicable to low- and middle-income countries (LMICs) with distinct healthcare challenges. This study aims to characterize LC care intervals and their barriers in a Latin American LMIC.METHODSThis analysis of patients with LC diagnosed between 2003 and 2016 at a national cancer referral center, calculated the duration of the following six intervals: from symptom onset to first specialist visit (StFS), first specialist visit to diagnosis (FStDX), diagnosis to treatment initiation (DXtTX), symptom onset to diagnosis (StDX), first specialist visit to treatment (FStTX), and symptom onset to treatment (StTX). Clinicopathological and sociodemographic characteristics were extracted from electronic medical records. Multivariate Cox regression was used to identify factors associated with the duration of each care interval.RESULTS503 patients were included; the majority were females (52.7%), with adenocarcinoma (76%) and a positive smoking status (56%). The median duration in days (interquartile range [IQR]) of StFS, FStDX, DXtTX, StDX, FStTX, and StTX were 90 (142), 34 (63), 17 (25), 148 (149), 60 (79), and 173 (153), respectively. In multivariate analyses, factors associated with the length of care intervals were sex, marital status, disease stage, mutational status, asbestos, and wood smoke exposure. After adjustment, sex remained a statistically significant predictor of longer intervals.CONCLUSIONOur findings support the identification of barriers and the development of interventions aimed at shortening LC care intervals, particularly among disadvantaged individuals who are more likely to experience delays.

01 Jul 2025·Archives of Medical Research

Founder Variants in the Mexican Population: A Systematic Review

Article

Author: Metta-Harari, Teresa ; Taja-Chayeb, Lucia ; González-Barrios, Rodrigo ; Wegman-Ostrosky, Talia ; Harari-Arakindji, Sylvia ; Zatarain-Barrón, Zyanya Lucia ; Espino-Gutiérrez, Isabel ; García-Ortiz, José Elias

BACKGROUNDFounder variants (FVs) are genetic alterations inherited from a common ancestor that are frequently observed in genetically homogeneous populations. FVs significantly influence the prevalence of genetic disorders in specific populations; however, these variants have never been comprehensively described for the Mexican population.AIMThis systematic review aimed to summarize and describe FVs of Mexican origin and their association with specific health conditions.METHODSStudies were retrieved from the LILACS, COCHRANE, Scopus, and PubMed databases using a pre-specified search string. Information on genes, variants, and haplotypes that met the inclusion criteria was extracted from the articles. Based on the evidence provided, variants originating in the Mexican population were stratified according to whether they had strong or weak evidence for classification as FVs.RESULTSA total of 32 studies were selected, describing 19 genes and 21 FVs. These include variants associated with a variety of diseases, such as Stargardt disease, breast and ovarian cancer, Fanconi anemia, congenital muscular dystrophy, and familial hypercholesterolemia. Haplotype analysis revealed that some variants, although frequent in the Mexican population, appear to be of European origin, as their haplotypes match those found in European populations and may represent variants introduced into Mexican territory following the Spanish conquest in the early 16th century.CONCLUSIONThese results provide a comprehensive view of the FVs present in the Mexican population, increasing our understanding of the genetic architecture in this region. In addition, they provide a broad context to elucidate potential associations between FVs and clinical, historical, and cultural findings.

01 Jun 2025·Epilepsy & Behavior

Association between metabolic patterns in 18-FDG PET-CT scan and postsurgical seizure outcomes in patients with temporal lobe epilepsy

Article

Author: Díaz-Meneses, Iván ; Robles-Lomelín, Pilar ; Martínez-Juárez, Iris E ; Moreno-Jiménez, Sergio ; Kerik-Rotenberg, Nora ; Sebastián-Díaz, Mario A ; Camiro-Zúñiga, Antonio ; Vázquez-Cruz, Betsy C ; Fuentes-Calvo, Irving ; Gonzalez-Salido, Jimena ; Solís-Vivanco, Rodolfo ; Martínez-Medina, Salvador ; Rosales-García, Juan Salvador ; Vasquez-Lopez, Fernando ; Colado-Martinez, Jimena ; Gutiérrez-Aceves, Guillermo Axayacalt ; Arellano-Reynoso, Alfonso

INTRODUCTIONTemporal lobe epilepsy (TLE) is the most common type of drug-resistant epilepsy in adults, and surgery is a standard treatment, offering seizure freedom in 60-70 % of patients. Despite advanced imaging, many TLE patients show inconsistent MRI findings, making functional imaging such as 18-FDG PET-CT scans essential in identifying epileptogenic zones. This study aims to assess the association between concordant or non-concordant metabolic patterns in presurgical 18-FDG PET-CT scans and postoperative outcomes in TLE patients.METHODSThis retrospective, observational study included people with epilepsy (PWE) who underwent TLE surgery at a clinic in Mexico City and had a presurgical 18-FDG PET-CT scan. Seizure outcomes were measured using Engel and ILAE classifications at a two-year follow-up. The concordant group had only temporal hypometabolism ipsilateral to the epileptogenic zone, while the non-concordant group had normal, extratemporal, or bitemporal hypometabolism.RESULTSThe study included 49 PWE: 28 with concordant PET-CT scans and 21 with non-concordant scans. Comparisons of seizure outcomes using the Engel and ILAE classifications at two years post-surgery revealed no significant differences between the groups (p = 0.972 and p = 0.279, respectively). The use of anti-seizure medications (ASM) after surgery did not differ significantly between groups (p = 0.649).CONCLUSIONAt our center, preoperative evaluation emphasizes the alignment of clinical findings, video-EEG, and MRI. At the two-year follow-up, no significant difference in seizure freedom was observed between patients with temporal lobe hypometabolism alone and those with other patterns.

100 Deals associated with Instituto Nacional de Cancerología

100 Translational Medicine associated with Instituto Nacional de Cancerología

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 31 May 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Instituto Nacional de Cancerología

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 31 May 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing